Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail

L. A. Drake, D. Babel, D. M. Stewart, Phoebe Rich, M. R. Ling, D. Breneman, R. K. Scher, A. G. Martin, D. M. Pariser, R. J. Pariser, C. N. Ellis, S. Kang, H. I. Katz, C. J. McDonald, J. Muglia, R. C. Savin, G. Webster, B. E. Elewski, J. J. Leyden, A. D. Bucko & 13 others E. H. Tschen, Jon Hanifin, M. R. Morman, J. L. Shupack, N. Levine, N. J. Lowe, W. F. Bergfeld, C. Camisa, D. S. Feingold, N. Konnikov, R. B. Odom, R. Aly, D. L. Greer

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Onychomycosis is a prevalent infection of the nail caused primarily by dermatophytes. Fluconazole is active in vitro against the most common pathogens, penetrates into the nail bed, and is clinically effective in the treatment of a wide variety of fungal infections. Objective: The purpose of this study was to assess the safety and efficacy of oral fluconazole 150, 300, and 450 mg administered once weekly compared with placebo in the treatment of distal subungual onychomycosis of the fingernail caused by dermatophytes. Methods: This was a multicenter, randomized, double- blind, placebo-controlled study enrolling 349 patients with onychomycosis of the fingernails. Clinical and mycologic efficacy as well as measures of safety were assessed monthly for a maximum of 9 months of treatment, with additional safety visits occurring at weeks 2 and 6. For inclusion, patients were required to have clinically and mycologically documented onychomycosis of the fingernail caused by dermatophytes with at least 25% involvement of the target fingernail. After end of therapy, patients with improved or cured fingenails entered a blinded 6-month follow-up without drug treatment during which efficacy was assessed every 2 months. Efficacy was assessed by clinical (visual) and mycologic (microscopic and culture) measures. Clinical measures included assessments of the percentage of target nail involvement, measurement of the distance from the nail fold to the proximal onychomycotic border, and signs and symptoms of onychomycosis. Results: Fluconazole was significantly superior to placebo in eradicating clinical and mycologic symptoms of onychomycosis, both at the end of active treatment and at 6 months after treatment (p = 0.0001 for all efficacy measures). At the end of therapy, 91% to 100% of patients in the fluconazole groups were judged clinical successes, defined as reduction of the affected area of the target nail to less than 25% or cure, compared with 8% for placebo. Clinical cure rates at end of therapy were 76%, 85%, and 90% for fluconazole 150, 300, and 450 mg, respectively, compared with 3% for placebo. These clinical success and cure rates were largely maintained or improved during follow-up. Clinical relapse in cured patients during the follow-up period was very low (1.5% to 3.3%). Fluconazole demonstrated mycologic eradication rates of 89% to 100% at the end of treatment and 90% to 99% at the end of follow-up; for placebo the rates were 8% and 12%, respectively. Conclusion: Fluconazole administered once weekly is safe and effective in eradicating distal subungual onychomycosis of the fingernail caused by dermatophytes.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
Volume38
Issue number6 II
StatePublished - 1998
Externally publishedYes

Fingerprint

Onychomycosis
Fluconazole
Nails
Arthrodermataceae
Placebos
Therapeutics
Safety
Mycoses
Signs and Symptoms

ASJC Scopus subject areas

  • Dermatology

Cite this

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. / Drake, L. A.; Babel, D.; Stewart, D. M.; Rich, Phoebe; Ling, M. R.; Breneman, D.; Scher, R. K.; Martin, A. G.; Pariser, D. M.; Pariser, R. J.; Ellis, C. N.; Kang, S.; Katz, H. I.; McDonald, C. J.; Muglia, J.; Savin, R. C.; Webster, G.; Elewski, B. E.; Leyden, J. J.; Bucko, A. D.; Tschen, E. H.; Hanifin, Jon; Morman, M. R.; Shupack, J. L.; Levine, N.; Lowe, N. J.; Bergfeld, W. F.; Camisa, C.; Feingold, D. S.; Konnikov, N.; Odom, R. B.; Aly, R.; Greer, D. L.

In: Journal of the American Academy of Dermatology, Vol. 38, No. 6 II, 1998.

Research output: Contribution to journalArticle

Drake, LA, Babel, D, Stewart, DM, Rich, P, Ling, MR, Breneman, D, Scher, RK, Martin, AG, Pariser, DM, Pariser, RJ, Ellis, CN, Kang, S, Katz, HI, McDonald, CJ, Muglia, J, Savin, RC, Webster, G, Elewski, BE, Leyden, JJ, Bucko, AD, Tschen, EH, Hanifin, J, Morman, MR, Shupack, JL, Levine, N, Lowe, NJ, Bergfeld, WF, Camisa, C, Feingold, DS, Konnikov, N, Odom, RB, Aly, R & Greer, DL 1998, 'Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail', Journal of the American Academy of Dermatology, vol. 38, no. 6 II.
Drake, L. A. ; Babel, D. ; Stewart, D. M. ; Rich, Phoebe ; Ling, M. R. ; Breneman, D. ; Scher, R. K. ; Martin, A. G. ; Pariser, D. M. ; Pariser, R. J. ; Ellis, C. N. ; Kang, S. ; Katz, H. I. ; McDonald, C. J. ; Muglia, J. ; Savin, R. C. ; Webster, G. ; Elewski, B. E. ; Leyden, J. J. ; Bucko, A. D. ; Tschen, E. H. ; Hanifin, Jon ; Morman, M. R. ; Shupack, J. L. ; Levine, N. ; Lowe, N. J. ; Bergfeld, W. F. ; Camisa, C. ; Feingold, D. S. ; Konnikov, N. ; Odom, R. B. ; Aly, R. ; Greer, D. L. / Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. In: Journal of the American Academy of Dermatology. 1998 ; Vol. 38, No. 6 II.
@article{bcbaf143d2774a35bf787a342ec04f9d,
title = "Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail",
abstract = "Background: Onychomycosis is a prevalent infection of the nail caused primarily by dermatophytes. Fluconazole is active in vitro against the most common pathogens, penetrates into the nail bed, and is clinically effective in the treatment of a wide variety of fungal infections. Objective: The purpose of this study was to assess the safety and efficacy of oral fluconazole 150, 300, and 450 mg administered once weekly compared with placebo in the treatment of distal subungual onychomycosis of the fingernail caused by dermatophytes. Methods: This was a multicenter, randomized, double- blind, placebo-controlled study enrolling 349 patients with onychomycosis of the fingernails. Clinical and mycologic efficacy as well as measures of safety were assessed monthly for a maximum of 9 months of treatment, with additional safety visits occurring at weeks 2 and 6. For inclusion, patients were required to have clinically and mycologically documented onychomycosis of the fingernail caused by dermatophytes with at least 25{\%} involvement of the target fingernail. After end of therapy, patients with improved or cured fingenails entered a blinded 6-month follow-up without drug treatment during which efficacy was assessed every 2 months. Efficacy was assessed by clinical (visual) and mycologic (microscopic and culture) measures. Clinical measures included assessments of the percentage of target nail involvement, measurement of the distance from the nail fold to the proximal onychomycotic border, and signs and symptoms of onychomycosis. Results: Fluconazole was significantly superior to placebo in eradicating clinical and mycologic symptoms of onychomycosis, both at the end of active treatment and at 6 months after treatment (p = 0.0001 for all efficacy measures). At the end of therapy, 91{\%} to 100{\%} of patients in the fluconazole groups were judged clinical successes, defined as reduction of the affected area of the target nail to less than 25{\%} or cure, compared with 8{\%} for placebo. Clinical cure rates at end of therapy were 76{\%}, 85{\%}, and 90{\%} for fluconazole 150, 300, and 450 mg, respectively, compared with 3{\%} for placebo. These clinical success and cure rates were largely maintained or improved during follow-up. Clinical relapse in cured patients during the follow-up period was very low (1.5{\%} to 3.3{\%}). Fluconazole demonstrated mycologic eradication rates of 89{\%} to 100{\%} at the end of treatment and 90{\%} to 99{\%} at the end of follow-up; for placebo the rates were 8{\%} and 12{\%}, respectively. Conclusion: Fluconazole administered once weekly is safe and effective in eradicating distal subungual onychomycosis of the fingernail caused by dermatophytes.",
author = "Drake, {L. A.} and D. Babel and Stewart, {D. M.} and Phoebe Rich and Ling, {M. R.} and D. Breneman and Scher, {R. K.} and Martin, {A. G.} and Pariser, {D. M.} and Pariser, {R. J.} and Ellis, {C. N.} and S. Kang and Katz, {H. I.} and McDonald, {C. J.} and J. Muglia and Savin, {R. C.} and G. Webster and Elewski, {B. E.} and Leyden, {J. J.} and Bucko, {A. D.} and Tschen, {E. H.} and Jon Hanifin and Morman, {M. R.} and Shupack, {J. L.} and N. Levine and Lowe, {N. J.} and Bergfeld, {W. F.} and C. Camisa and Feingold, {D. S.} and N. Konnikov and Odom, {R. B.} and R. Aly and Greer, {D. L.}",
year = "1998",
language = "English (US)",
volume = "38",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6 II",

}

TY - JOUR

T1 - Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail

AU - Drake, L. A.

AU - Babel, D.

AU - Stewart, D. M.

AU - Rich, Phoebe

AU - Ling, M. R.

AU - Breneman, D.

AU - Scher, R. K.

AU - Martin, A. G.

AU - Pariser, D. M.

AU - Pariser, R. J.

AU - Ellis, C. N.

AU - Kang, S.

AU - Katz, H. I.

AU - McDonald, C. J.

AU - Muglia, J.

AU - Savin, R. C.

AU - Webster, G.

AU - Elewski, B. E.

AU - Leyden, J. J.

AU - Bucko, A. D.

AU - Tschen, E. H.

AU - Hanifin, Jon

AU - Morman, M. R.

AU - Shupack, J. L.

AU - Levine, N.

AU - Lowe, N. J.

AU - Bergfeld, W. F.

AU - Camisa, C.

AU - Feingold, D. S.

AU - Konnikov, N.

AU - Odom, R. B.

AU - Aly, R.

AU - Greer, D. L.

PY - 1998

Y1 - 1998

N2 - Background: Onychomycosis is a prevalent infection of the nail caused primarily by dermatophytes. Fluconazole is active in vitro against the most common pathogens, penetrates into the nail bed, and is clinically effective in the treatment of a wide variety of fungal infections. Objective: The purpose of this study was to assess the safety and efficacy of oral fluconazole 150, 300, and 450 mg administered once weekly compared with placebo in the treatment of distal subungual onychomycosis of the fingernail caused by dermatophytes. Methods: This was a multicenter, randomized, double- blind, placebo-controlled study enrolling 349 patients with onychomycosis of the fingernails. Clinical and mycologic efficacy as well as measures of safety were assessed monthly for a maximum of 9 months of treatment, with additional safety visits occurring at weeks 2 and 6. For inclusion, patients were required to have clinically and mycologically documented onychomycosis of the fingernail caused by dermatophytes with at least 25% involvement of the target fingernail. After end of therapy, patients with improved or cured fingenails entered a blinded 6-month follow-up without drug treatment during which efficacy was assessed every 2 months. Efficacy was assessed by clinical (visual) and mycologic (microscopic and culture) measures. Clinical measures included assessments of the percentage of target nail involvement, measurement of the distance from the nail fold to the proximal onychomycotic border, and signs and symptoms of onychomycosis. Results: Fluconazole was significantly superior to placebo in eradicating clinical and mycologic symptoms of onychomycosis, both at the end of active treatment and at 6 months after treatment (p = 0.0001 for all efficacy measures). At the end of therapy, 91% to 100% of patients in the fluconazole groups were judged clinical successes, defined as reduction of the affected area of the target nail to less than 25% or cure, compared with 8% for placebo. Clinical cure rates at end of therapy were 76%, 85%, and 90% for fluconazole 150, 300, and 450 mg, respectively, compared with 3% for placebo. These clinical success and cure rates were largely maintained or improved during follow-up. Clinical relapse in cured patients during the follow-up period was very low (1.5% to 3.3%). Fluconazole demonstrated mycologic eradication rates of 89% to 100% at the end of treatment and 90% to 99% at the end of follow-up; for placebo the rates were 8% and 12%, respectively. Conclusion: Fluconazole administered once weekly is safe and effective in eradicating distal subungual onychomycosis of the fingernail caused by dermatophytes.

AB - Background: Onychomycosis is a prevalent infection of the nail caused primarily by dermatophytes. Fluconazole is active in vitro against the most common pathogens, penetrates into the nail bed, and is clinically effective in the treatment of a wide variety of fungal infections. Objective: The purpose of this study was to assess the safety and efficacy of oral fluconazole 150, 300, and 450 mg administered once weekly compared with placebo in the treatment of distal subungual onychomycosis of the fingernail caused by dermatophytes. Methods: This was a multicenter, randomized, double- blind, placebo-controlled study enrolling 349 patients with onychomycosis of the fingernails. Clinical and mycologic efficacy as well as measures of safety were assessed monthly for a maximum of 9 months of treatment, with additional safety visits occurring at weeks 2 and 6. For inclusion, patients were required to have clinically and mycologically documented onychomycosis of the fingernail caused by dermatophytes with at least 25% involvement of the target fingernail. After end of therapy, patients with improved or cured fingenails entered a blinded 6-month follow-up without drug treatment during which efficacy was assessed every 2 months. Efficacy was assessed by clinical (visual) and mycologic (microscopic and culture) measures. Clinical measures included assessments of the percentage of target nail involvement, measurement of the distance from the nail fold to the proximal onychomycotic border, and signs and symptoms of onychomycosis. Results: Fluconazole was significantly superior to placebo in eradicating clinical and mycologic symptoms of onychomycosis, both at the end of active treatment and at 6 months after treatment (p = 0.0001 for all efficacy measures). At the end of therapy, 91% to 100% of patients in the fluconazole groups were judged clinical successes, defined as reduction of the affected area of the target nail to less than 25% or cure, compared with 8% for placebo. Clinical cure rates at end of therapy were 76%, 85%, and 90% for fluconazole 150, 300, and 450 mg, respectively, compared with 3% for placebo. These clinical success and cure rates were largely maintained or improved during follow-up. Clinical relapse in cured patients during the follow-up period was very low (1.5% to 3.3%). Fluconazole demonstrated mycologic eradication rates of 89% to 100% at the end of treatment and 90% to 99% at the end of follow-up; for placebo the rates were 8% and 12%, respectively. Conclusion: Fluconazole administered once weekly is safe and effective in eradicating distal subungual onychomycosis of the fingernail caused by dermatophytes.

UR - http://www.scopus.com/inward/record.url?scp=18144446912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144446912&partnerID=8YFLogxK

M3 - Article

VL - 38

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 6 II

ER -